Adenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
This review article focuses on the role of adenosine in coronary artery disease (CAD) diagnosis and treatment. Adenosine, an endogenous purine nucleoside, plays crucial roles in cardiovascular physiology and pathology. Its release and effects, mediated by specific receptors, influence vasomotor function, blood pressure regulation, heart rate, and platelet activity. Adenosine therapeutic effects include treatment of the no-reflow phenomenon and paroxysmal supraventricular tachycardia. The production of adenosine involves complex cellular pathways, with extracellular and intracellular synthesis mechanisms. Adenosine’s rapid metabolism underscores its short half-life and physiological turnover. Furthermore, adenosine’s involvement in side effects of antiplatelet therapy, particularly ticagrelor and cangrelor, highlights its clinical significance. Moreover, adenosine serves as a valuable tool in CAD diagnosis, aiding stress testing modalities and guiding intracoronary physiological assessments. Its use in assessing epicardial stenosis and microvascular dysfunction is pivotal for treatment decisions. Overall, understanding adenosine’s mechanisms and clinical implications is essential for optimizing CAD management strategies, encompassing both therapeutic interventions and diagnostic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
Murry, C. E., Jennings, R. B., & Reimer, K. A. (1986) · Circulation · doi:10.1161/01.cir.74.5.1124 · Cited by 7,812 · cited 1×
“Ischemic preconditioning is defined as a brief transient ischemia before an episode of more prolonged ischemia, which makes the myocardium more resistant to ischemia-reperfusion injury [30].”
Background2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · cited 2×
“The incidence of dyspnea in patients treated with ticagrelor varies in different studies, from 13.8% in the PLATO trial [43] to 20% in the more recent TWILIGHT trial [44].”
BackgroundMethodInfluential2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333 · cited 3×
“The latest ESC guidelines on ACS and CCS [38,40] and many expert consensus documents support the use of coronary physiological assessment to guide PCI, in particular in angiographically intermediate coronary stenosis.”
BackgroundMethodChesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., Dodge, H. T., Francis, C. K., Hillis, D., & Ludbrook, P. (1987) · Circulation · doi:10.1161/01.cir.76.1.142 · Cited by 2,244
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001029 · Cited by 1,611
Liu, G. S., Thornton, J., Van Winkle, D. M., Stanley, A. W., Olsson, R. A., & Downey, J. M. (1991) · Circulation · doi:10.1161/01.cir.84.1.350 · Cited by 1,351 · cited 1×
“This process is thought to be mediated by endogenous adenosine through the activation of A 1 R and A 3 R [31,32].”
Backgroundvan ‘t Hof, A. W. J., Liem, A., Suryapranata, H., Hoorntje, J. C. A., de Boer, M.-J., & Zijlstra, F. (1998) · Circulation · doi:10.1161/01.cir.97.23.2302 · Cited by 1,307
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Pijls, N. H., van Son, J. A., Kirkeeide, R. L., De Bruyne, B., & Gould, K. L. (1993) · Circulation · doi:10.1161/01.cir.87.4.1354 · Cited by 1,183 · cited 1×
“Almost 30 years ago it was demonstrated that, under the condition of maximal hyperemia, the ratio of the pressure distal to the coronary stenosis to the aortic pressure was linear, and correlated with the ratio of the Doppler-derived flow velocity [73].”
BackgroundTicagrelor with or without Aspirin in High-Risk Patients after PCI
Mehran, R., Baber, U., Sharma, S. K., Cohen, D. J., Angiolillo, D. J., Briguori, C., Cha, J. Y., Collier, T., Dangas, G., Dudek, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908419 · Cited by 1,039 · cited 1×
“The incidence of dyspnea in patients treated with ticagrelor varies in different studies, from 13.8% in the PLATO trial [43] to 20% in the more recent TWILIGHT trial [44].”
BackgroundInfluentialCardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow
Berne, R. M. (1963) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1963.204.2.317 · Cited by 1,012
Nucleotide signalling during inflammation
Idzko, M., Ferrari, D., & Eltzschig, H. K. (2014) · Nature · doi:10.1038/nature13085 · Cited by 902 · cited 1×
“It is released mostly in the context of ischemia, beta-adrenergic stimulation, hypoxia, and inflammation [1,2].”
BackgroundAdenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895 · cited 2×
“The intracellular synthesis of adenosine is a consequence of hydrolysis of AMP and S-adenosyl-L-homocysteine mediated by CD73 and SAH hydrolase [5].”
Background2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.053 · Cited by 824
Kunadian, V., Chieffo, A., Camici, P. G., Berry, C., Escaned, J., Maas, A. H. E. M., Prescott, E., Karam, N., Appelman, Y., Fraccaro, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa503 · Cited by 795 · cited 1×
“In recent years, there has been a growing interest in patients with angina and/or ischemia with non-obstructive coronary artery disease (ANOCA and/or INOCA), leading to a “full physiology” coronary assessment approach [75].”
BackgroundPharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783 · cited 3×
“The main effects of adenosine on the cardiovascular system effects are on vasomotor function and blood pressure regulation, heart rate, and platelet activity [3].”
BackgroundPreconditioning the human myocardium
Yellon, D. M., Alkhulaifi, A. M., & Pugsley, W. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)91819-8 · Cited by 712 · cited 1×
“Ischemic preconditioning thorough mechanical occlusion of coronary arteries in patients undergoing coronary artery bypass grafting (CABG) [33] and elective PCI [34] has been shown to improve outcomes in small studies.”
BackgroundASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers
Henzlova, M. J., Duvall, W. L., Einstein, A. J., Travin, M. I., & Verberne, H. J. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0387-x · Cited by 700 · cited 1×
“Adenosine, dipyridamole, and regadenoson are used as equivalent coronary vasodilators during cardiac stress testing [70].”
BackgroundRezkalla, S. H., & Kloner, R. A. (2002) · Circulation · doi:10.1161/hc0502.102867 · Cited by 621 · cited 4×
“In SVGs PCI pretreatment with intracoronary vasodilators and the use of coronary filter should be considered [56].”
BackgroundMethodInfluentialRoss, A. M., Gibbons, R. J., Stone, G. W., Kloner, R. A., & Alexander, R. W. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.061 · Cited by 610
Deutsch, E., Berger, M., Kussmaul, W. G., Hirshfeld, J. W., Herrmann, H. C., & Laskey, W. K. (1990) · Circulation · doi:10.1161/01.cir.82.6.2044 · Cited by 594 · cited 1×
“Ischemic preconditioning thorough mechanical occlusion of coronary arteries in patients undergoing coronary artery bypass grafting (CABG) [33] and elective PCI [34] has been shown to improve outcomes in small studies.”
BackgroundAngiolillo, D. J., Firstenberg, M. S., Price, M. J., Tummala, P. E., Hutyra, M., Welsby, I. J., Voeltz, M. D., Chandna, H., Ramaiah, C., Brtko, M., et al. (2012) · JAMA · doi:10.1001/jama.2011.2002 · Cited by 481 · cited 1×
“The BRIDGE trial [53] demonstrated the efficacy of intravenous cangrelor in the maintenance of high levels of platelet inhibition in patients discontinuing thienopyridines for cardiac surgery.”
BackgroundCerqueira, M. D., Verani, M. S., Schwaiger, M., Heo, J., & Iskandrian, A. S. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90424-3 · Cited by 464
Liver X receptor in cholesterol metabolism
Zhao, C., & Dahlman-Wright, K. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0271 · Cited by 418 · cited 1×
“Oxysterols, by activating LXR, further enhance expression of ABCA1 and ABCG1, counteracting inflammatory cytokine-induced suppression of these proteins [29].”
BackgroundPurinergic Signaling in the Cardiovascular System
Burnstock, G. (2017) · Circulation Research · doi:10.1161/circresaha.116.309726 · Cited by 415
Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention
Jaffe, R., Charron, T., Puley, G., Dick, A., & Strauss, B. H. (2008) · Circulation · doi:10.1161/circulationaha.107.742312 · Cited by 408 · cited 2×
“High thrombus burden is the main angiographic risk factor [56,60,61].”
BackgroundIonic basis of the electrophysiological actions of adenosine on cardiomyocytes
Belardinelli, L., Shryock, J. C., Song, Y., Wang, D., & Srinivas, M. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.5.7896004 · Cited by 289
Liu, G. S., Richards, S. C., Olsson, R. A., Mullane, K., Walsh, R. S., & Downey, J. M. (1994) · Cardiovascular Research · doi:10.1093/cvr/28.7.1057 · Cited by 276
Regulation of Neutrophil Function by Adenosine
Barletta, K. E., Ley, K., & Mehrad, B. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226845 · Cited by 260 · cited 1×
“Adenosine impacts different immune cells differently; while it inhibits neutrophil adhesion and migration through A 2A R and A 2B R, it promotes inflammation in these cells through A 1 R and A 3 R [24,25].”
BackgroundManagement of No-Reflow Phenomenon in the Catheterization Laboratory
Rezkalla, S. H., Stankowski, R. V., Hanna, J., & Kloner, R. A. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.11.059 · Cited by 255 · cited 2×
“High thrombus burden is the main angiographic risk factor [56,60,61].”
BackgroundKloner, R. A., Forman, M. B., Gibbons, R. J., Ross, A. M., Alexander, R. W., & Stone, G. W. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl094 · Cited by 253 · cited 1×
“A separate analysis of the AMISTAD-II trial showed that adenosine was linked to better clinical outcome in patients who underwent early reperfusion [64].”
MethodMustafa, S. J., Morrison, R. R., Teng, B., & Pelleg, A. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-89615-9_6 · Cited by 251
Preconditioning of Human Myocardium With Adenosine During Coronary Angioplasty
Leesar, M. A., Stoddard, M., Ahmed, M., Broadbent, J., & Bolli, R. (1997) · Circulation · doi:10.1161/01.cir.95.11.2500 · Cited by 244 · cited 1×
“One small randomized trial of 30 patients showed effective myocardial precondition through 10 min intracoronary adenosine infusion at 2 mg/min vs. normal saline before elective PCI [35].”
BackgroundCardiovascular adenosine receptors: Expression, actions and interactions
Headrick, J. P., Ashton, K. J., Rose'Meyer, R. B., & Peart, J. N. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.002 · Cited by 228
Regulation of Macrophage Function by Adenosine
Haskó, G., & Pacher, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226852 · Cited by 223
Shaw, L. J., Berman, D. S., Picard, M. H., Friedrich, M. G., Kwong, R. Y., Stone, G. W., Senior, R., Min, J. K., Hachamovitch, R., Scherrer-Crosbie, M., et al. (2014) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2013.10.021 · Cited by 207 · cited 3×
“An area of ischemia involving 10% or more of the left ventricle myocardium is considered to be at high risk of events [71].”
BackgroundInfluentialEltzschig, H. K., Faigle, M., Knapp, S., Karhausen, J., Ibla, J., Rosenberger, P., Odegard, K. C., Laussen, P. C., Thompson, L. F., & Colgan, S. P. (2006) · Blood · doi:10.1182/blood-2006-02-001016 · Cited by 188 · cited 1×
“It is released mostly in the context of ischemia, beta-adrenergic stimulation, hypoxia, and inflammation [1,2].”
BackgroundIonic mechanisms of adenosine actions in pacemaker cells from rabbit heart.
Belardinelli, L., Giles, W. R., & West, A. (1988) · The Journal of Physiology · doi:10.1113/jphysiol.1988.sp017352 · Cited by 181
Role of adenosine in the heart and circulation
Mubagwa, K., Mullane, K., & Flameng, W. J. (1996) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00140-x · Cited by 169
Adenosine receptors and asthma
Brown, R. A., Spina, D., & Page, C. P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.22 · Cited by 163 · cited 1×
“Dyspnea is the consequence of the activation of A 1 R and A 2A R in the vagal C fibers on the bronchial wall [41], while bradyarrhythmia is mediated mainly by the activation of A 1 R. Dyspnea and bradyarrhythmias are usually temporary and tend to self-resolve in a few days because, in the context…”
BackgroundRankin, A. C., Oldroyd, K. G., Chong, E., Rae, A. P., & Cobbe, S. M. (1989) · Heart · doi:10.1136/hrt.62.3.195 · Cited by 161 · cited 1×
“From a diagnostic point of view, adenosine, causing transient AVB, can reveal atrial flutter or atrial fibrillation and aid in the differential diagnosis in broad complex tachycardias [69].”
BackgroundAdenosine and the Cardiovascular System
Reiss, A. B., Grossfeld, D. J., Kasselman, L. J., Renna, H. A., Vernice, N. A., Drewes, W., Konig, J., Carsons, S. E., & DeLeon, J. R. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00345-5 · Cited by 157 · cited 1×
“ABCA1 and ABCG1 facilitate cholesterol efflux to form HDL, while cholesterol 27-hydroxylase converts cholesterol into 27-hydroxycholesterol, aiding its removal from cells [27].”
BackgroundRelationship between coronary flow and adenosine production and release
Rubio, R. (1974) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(74)90036-4 · Cited by 153 · cited 1×
“However, once myocardial perfusion is restored, adenosine levels tend to normalize [42].”
BackgroundNiccoli, G., Rigattieri, S., Vita, M. R. D., Valgimigli, M., Corvo, P., Fabbiocchi, F., Romagnoli, E., Caterina, A. R. D., Torre, G. L., Schiavo, P. L., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.02.009 · Cited by 135 · cited 2×
“…investigating the effects of adenosine on outcomes following PCI for STEMI were the AMISTAD (Acute Myocardial Infarction Study of Adenosine) trial [62] and AMISTAD-II trial [63]; these trials demonstrated a significant reduction in infarct size with infusion of high-dose adenosine, with no…”
BackgroundMethodScirica, B. M., Cannon, C. P., Emanuelsson, H., Michelson, E. L., Harrington, R. A., Husted, S., James, S. K., Katus, H. A., Pais, P., Raev, D. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.056 · Cited by 133 · cited 1×
“The incidence of bradyarrhythmias related to ticagrelor in the PLATO trial [43] was investigated by Scirica et al. [47].”
MethodAdenosine and the Cardiovascular System: The Good and the Bad
Guieu, R., Deharo, J., Maille, B., Crotti, L., Torresani, E., Brignole, M., & Parati, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051366 · Cited by 133 · cited 2×
“Adenosine e ff ects are mediated by four GPCRs: activation of A 1 R leads to slowing of the heart rate, activation of A 2A R and A 2B R leads to vasodilation, and A 3 R is implicated in the protection against the ischemia/reperfusion process [6] (Figure 1).”
BackgroundAdenosine signaling during acute and chronic disease states
Karmouty-Quintana, H., Xia, Y., & Blackburn, M. R. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0997-1 · Cited by 131
Purinergic Regulation of Neutrophil Function
Wang, X., & Chen, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00399 · Cited by 120 · cited 1×
“Adenosine impacts different immune cells differently; while it inhibits neutrophil adhesion and migration through A 2A R and A 2B R, it promotes inflammation in these cells through A 1 R and A 3 R [24,25].”
BackgroundCardiac effects of adenosine in A 2A receptor knockout hearts: uncovering A 2B receptors
Morrison, R. R., Talukder, M. A. H., Ledent, C. A., & Mustafa, S. J. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00723.2001 · Cited by 110
P1 receptors and cytokine secretion
Abbracchio, M. P., & Ceruti, S. (2007) · Purinergic Signalling · doi:10.1007/s11302-006-9033-z · Cited by 80 · cited 1×
“For instance, while low adenosine concentrations activate A 1 R, associated with pro-inflammatory activity, higher concentrations primarily engage other receptors with anti-inflammatory effects, creating a negative feedback loop on the immune system [21–23].”
BackgroundCaiazzo, G., Musci, R. L., Frediani, L., Umińska, J. M., Wańha, W., Filipiak, K. J., Kubica, J., & Navarese, E. P. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2020.07.001 · Cited by 68 · cited 2×
“The mechanisms behind this phenomenon are several: microvascular obstruction due to distal embolization of thrombus or debris, microvascular spasm, intravascular plugging from platelet microthrombi or leukocytes, and ischemia-reperfusion injury [56,59,61].”
BackgroundTargeting Adenosine Receptors for the Treatment of Cardiac Fibrosis
Vecchio, E. A., White, P. J., & May, L. T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00243 · Cited by 60 · cited 1×
“Some evidence [79] suggests that adenosine signaling pathways play a critical role in regulating cardiac remodeling processes, including fibroblast activation, extracellular matrix deposition, and inflammation, so this field should be explored as it can have a therapeutic role in the prevention of…”
BackgroundSanjani, M. S., Teng, B., Krahn, T., Tilley, S., Ledent, C. A., & Mustafa, S. J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00052.2011 · Cited by 59
Personalised antiplatelet therapies for coronary artery disease: what the future holds
Capodanno, D., & Angiolillo, D. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad362 · Cited by 58 · cited 1×
“In the event of a switch, genetic testing before or platelet reactivity testing after may be considered [46].”
BackgroundZhao, Z., Francis, C. E., & Ravid, K. (1997) · Microvascular Research · doi:10.1006/mvre.1997.2044 · Cited by 55 · cited 1×
“A 3 R is poorly represented in myocardial tissue but is present in smooth muscle cells of coronary arteries [20].”
BackgroundBlood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy
Wolska, N., & Różalski, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215475 · Cited by 48 · cited 1×
“A 2A R and A 2A R are expressed on platelets and their activation has antiplatelet effects via inhibition of calcium flux [19].”
BackgroundScarsini, R., Campo, G. C., Serafino, L. D., Zanon, S., Rubino, F., Monizzi, G., Biscaglia, S., Ancona, M., Polimeni, A., Niccoli, G., et al. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.23.06414-1 · Cited by 46
Khan, K. A., Qamar, N., Saghir, T., Sial, J. A., Kumar, D., Kumar, R., Qayyum, D., Yasin, U., Jalbani, J., & Karim, M. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011408 · Cited by 42 · cited 1×
“The recently published COAR trial [65] compared epinephrine and adenosine in treatment of NRP, showing a better improvement in the coronary flow with epinephrine (more TFG > 3 and better corrected TIMI frame count), with no significant difference in the final Myocardial Blush Grade 3, and with a…”
MethodNavarese, E. P., Buffon, A., Andreotti, F., Gurbel, P. A., Koziński, M., Kubica, A., Musumeci, G., Cremonesi, A., Tavazzi, L., Kubica, J., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.001 · Cited by 41 · cited 1×
“…adenosine infusion reduced post-procedural no-reflow, with no benefits in term of mortality, re-myocardial infarction and ST-segment resolution [66,67], while in another a favorable result appeared, with a significant increase in left ventricular function, a reduction in incidence of heart…”
BackgroundSpecies comparison of adenosine and β-adrenoceptors in mammalian atrial and ventricular myocardium
Musser, B., Morgan, M. E., Leid, M. E., Murray, T. F., Linden, J. M., & Vestal, R. E. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90086-o · Cited by 40 · cited 1×
“A 2A R is particularly expressed in the atrium and ventricular tissues, in the vessels and specifically in smooth muscle cells of coronary arteries [7–9 , 14].”
BackgroundImpact of intracoronary adenosine administration during primary PCI: A meta-analysis
Polimeni, A., Rosa, S. D., Sabatino, J., Sorrentino, S., & Indolfi, C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.086 · Cited by 39 · cited 1×
“…term of mortality, re-myocardial infarction and ST-segment resolution [66,67], while in another a favorable result appeared, with a significant increase in left ventricular function, a reduction in incidence of heart failure and a lower incidence of major adverse cardiovascular events (MACEs) [68].”
BackgroundHussain, T., & Mustafa, S. J. (1995) · Circulation Research · doi:10.1161/01.res.77.1.194 · Cited by 37
Gao, Q., Yang, B., Guo, Y., & Zheng, F. (2015) · Medicine · doi:10.1097/md.0000000000001279 · Cited by 31 · cited 1×
“…adenosine infusion reduced post-procedural no-reflow, with no benefits in term of mortality, re-myocardial infarction and ST-segment resolution [66,67], while in another a favorable result appeared, with a significant increase in left ventricular function, a reduction in incidence of heart…”
BackgroundDifferential sensitivity of cardiac pacemakers to exogenous adenosine in vivo
Pelleg, A., Hurt, C. M., Miyagawa, A., Michelson, E. L., & Dreifus, L. S. (1990) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1990.258.6.h1815 · Cited by 27
Bernhardt, P., Steffens, M., Kleinertz, K., Morell, R., Budde, R., Leischik, R., Krämer, A., Overhoff, U., & Strohm, O. (2006) · Journal of Cardiovascular Magnetic Resonance · doi:10.1080/10976640600575270 · Cited by 25 · cited 1×
“In another registry of patients undergoing MRI stress testing with adenosine, the incidence of side effects was lower (chest pain and dyspnea in 14% and nausea and vomiting in 5%); these different results can be explain by the lower dose of adenosine used in this protocol [77].”
ResultLuca, G. D., Iorio, S., Venegoni, L., & Marino, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.027 · Cited by 25
Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y12 antagonists
Boncler, M. A., Wzorek, J., Wolska, N., Polak, D., Watała, C. W., & Różalski, M. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.11.005 · Cited by 25 · cited 1×
“A recent in vitro study showed an inhibition of ADP-induced platelet activation after administration of selective and non-selective A 2A R agonists, indicating that adenosine receptor agonists could be a potential therapeutic option to enhance P2Y 12 inhibitor activity [37].”
BackgroundDyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
Angiolillo, D. J., Cao, D., Sartori, S., Baber, U., Dangas, G., Zhang, Z., Vogel, B., Kunadian, V., Briguori, C., Cohen, D. J., et al. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.08.019 · Cited by 25 · cited 1×
“Angiolillo et al. [45] analyzed dyspnea in the TWILIGHT trial and found that discontinuation of ticagrelor due to dyspnea occurred in 9.1% patients, in most of the cases (6.3”
BackgroundInfluentialVoloshyna, I., Carsons, S. E., Littlefield, M. J., Rieger, J. M., Figler, R. A., & Reiss, A. B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.11.005 · Cited by 24
Successful Reversal of Bradycardia and Dyspnea With Aminophylline After Ticagrelor Load
Minner, S. A., Simone, P. B., Chung, B., & Shah, A. P. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016680978 · Cited by 19 · cited 1×
“Some case reports [50,51] documented positive effects on ticagrelor-related brad-yarrhythmias and dyspnea with continuous infusion of aminophylline or theophylline, which act as a adenosine receptor antagonists.”
BackgroundReversal of Ticagrelor-Induced Arrhythmias and Cheyne–Stokes Respiration With Aminophylline Infusion
Conte, L., Pugliese, N. R., & Giannoni, A. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000518 · Cited by 18 · cited 1×
“Some case reports [50,51] documented positive effects on ticagrelor-related brad-yarrhythmias and dyspnea with continuous infusion of aminophylline or theophylline, which act as a adenosine receptor antagonists.”
BackgroundAdenosine-induced atrial fibrillation during fractional flow reserve measurement
Park, E., Price, A. D., & Vidovich, M. I. (2012) · Cardiology Journal · doi:10.5603/cj.2012.0121 · Cited by 13 · cited 1×
“Atrial fibrillation during adenosine infusion is reported in 12% of patients [78] and it is usually well tolerated in the absence of an accessory pathway, which can induce a high ventricular rate response which can degenerate in ventricular fibrillation.”
BackgroundNew directions in myocardial perfusion imaging
Beller, G. (1993) · Clinical Cardiology · doi:10.1002/clc.4960160203 · Cited by 12 · cited 1×
“The perfusion PET/SPECT aims to detect fixed or reversible perfusion defects: when the radiotracer is administered during vasodilator infusion, in the presence of epicardial coronary stenosis, a perfusion defect is observed, and delayed images then show if the defect is reversible [72].”
BackgroundCharacteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study
Parker, W. A., Bhatt, D. L., Prats, J., Day, J. R., Steg, P. G., Stone, G. W., Hamm, C. W., Mahaffey, K. W., Price, M. J., Gibson, C. M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0958 · Cited by 12 · cited 2×
“In the CHAMPION PHOENIX study, the incidence of dyspnea in patients treated with cangrelor was 1.2% (vs. 0.3% placebo group) and usually mild or moderate, leading to no discontinuation of the therapy [55].”
BackgroundInfluentialPathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report
Cesarini, D., Muraca, I., Berteotti, M., Gori, A. M., Sorrentino, A., Bertelli, A., Marcucci, R., & Valenti, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310844 · Cited by 9 · cited 1×
“Real-life cases involving relatively young patients without high bleeding risk (HBR) features, like the one reported by Cesarini et al. [48], should be switched to prasugrel.”
BackgroundSelf-citation“Tailored” antiplatelet bridging therapy with cangrelor: moving toward personalized medicine
Valenti, R., Muraca, I., Marcucci, R., Ciatti, F., Berteotti, M., Gori, A. M., Carrabba, N., Migliorini, A., Marchionni, N., & Valgimigli, M. (2021) · Platelets · doi:10.1080/09537104.2021.1983162 · Cited by 7 · cited 1×
“In this clinical context the administration of cangrelor may be prolonged for days and some authors suggest a tailored dose adjustment based on daily platelet reactivity testing to minimize side effects [54].”
BackgroundSelf-citationFilippo, C. D., Caniato, F., Cappelli, F., Mattesini, A., Meucci, F., Sori, A., Stolcova, M., Agostini, C., Bernardo, P., & Mario, C. D. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001042 · Cited by 5 · cited 2×
“Meanwhile older patients with one or more HBR features, like the one reported by Di Filippo et al. [49], should be switched to clopidogrel, possibly after the evaluation of the presence of loss-of-function alleles of the CYP2A19 enzyme.”
BackgroundLong-term dual antiplatelet therapy: pharmacological and clinical implications
Mario, C. D., Mugelli, A., Filardi, P. P., Rosano, G. M. C., & Rossi, F. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000677 · Cited by 3
Cited by
John, L., Dcunha, L., Ahmed, M., Thomas, S. D., Raju, R., & Jayanandan, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-00024-3 · Cited by 22
“Moreover, Marchi et al. (2024) suggest that adenosine-related drugs, including Cangrelor, may have unintentional cardiac and neurological effects due to their impact on ATP metabolism and purinergic signaling 82 .”
Ramirez, A. Y., Doman, E. R., Sanchez, K., & CHILTON, R. J. (2025) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000332 · Cited by 12
“Its potent arterial vasodilation, however, can lead to the coronary steal phenomenon, where blood flow is diverted from ischemic regions to nonsten-otic coronary arteries [25,26].”
Adenosine receptors as emerging therapeutic targets in epilepsy
Mal’tseva, V. N., Gaidin, S. G., & Kosenkov, A. M. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0121 · Cited by 5
“Both A2A and A2B receptor activation have been shown to induce vasodilation (Marchi et al. 2024).”
Wu, J., Zhao, J., Cheng, Y., Zhou, H., Shen, G., Ding, H., Lv, J., Dong, S., & Tang, O. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06295-8 · Cited by 4
“Ade-nosine, as a product of purine metabolism, can promote vasodilation by acting on specific receptors (such as A1 and A2 receptors), thereby lowering blood pressure [35, Fig.”
Special Issue “Adenosine Receptors in Health and Disease”
Vlajkovic, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212370 · Cited by 3
“A review by Marchi et al. [7] focuses on the role of adenosine in the diagnosis and treatment of coronary artery disease (CAD).”
Metadata
- Authors
- Marchi, E., Muraca, I., Berteotti, M., Gori, A. M., Valenti, R., & Marcucci, R.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Marchi, Enrico
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-05-28
- Volume
- 25
- Issue
- 11
- Pages
- 5852
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172110
- OpenAlex
- W4399092385
- Cited by
- 8
- References
- 82
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Keywords
- adenosine, coronary artery disease, adenosine receptors, no-reflow phenomenon, paroxysmal supraventricular tachycardia, adenosine metabolism, antiplatelet therapy, ticagrelor, cangrelor, stress testing, microvascular dysfunction, vasomotor function, platelet function
- MeSH terms
- Adenosine, Adenosine Monophosphate, Animals, Coronary Artery Disease, Humans, Platelet Aggregation Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.